Status:
UNKNOWN
Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Benign Disease
Eligibility:
All Genders
Up to 18 years
Brief Summary
determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.
Detailed Description
30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symp...
Eligibility Criteria
Inclusion
- 0 to 18 years
- allogeneic bone marrow transplantation for malignant or benign disease
- affiliation to French sécurité sociale
- parent's consent
Exclusion
- severe gastro-intestinal involvement before transplant
- previous digestive surgery
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00751452
Start Date
April 1 2008
End Date
September 1 2009
Last Update
January 19 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Etienne MERLIN
Clermont-Ferrand, France, 63003